SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses potential catalysts including upcoming news, partnerships, and the possibility of a major exchange listing. Bullish sentiment is fueled by comparisons to early XRP and anticipation of the Zebec Super App launch. Many believe ZBCN is positioned for significant growth and real-world adoption within the evolving financial landscape.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amidst discussions around its potential collaboration with Tesla and upcoming airshow demonstrations. Community members are actively debating the company's technology, particularly its flight time and vertical takeoff capabilities, with bullish and bearish investors staking their claims. The stock's high trading volume and short interest are also fueling speculation about a potential short squeeze.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF is trending as Bitcoin flirts with all-time highs, sparking community discussion around potential breakouts and resistance levels. Some traders are analyzing channel formations and key support areas, while others highlight bullish sentiment and potential upside targets. Community members are also watching how Bitcoin's performance influences related assets and meme coins, like WAGMI.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as it rallies to new all-time highs, sparking excitement and debate within the community about its future trajectory. Bullish sentiment prevails, with many anticipating further gains and dismissing bearish viewpoints, while others remain cautious of potential pullbacks. Discussions revolve around key price levels, long-term potential, and the influence of institutional investment.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Grayscale Ethereum Mini Trust is trending as the community discusses Ethereum's potential, particularly against the backdrop of a possible government shutdown and anticipation of a rate cut. Community members are actively speculating on ETH price movements and discussing potential targets, as well as comparing ETH to other cryptocurrencies like SOL and WAGMI. There's excitement around potential gains as well as discussions around institutional adoption.

ProPetro Holding Corp. is an oilfield services company that engages in the provision of hydraulic fracturing and other complementary services. It operates through the following segments: Hydraulic Fracturing, Wireline, Cementing, and All Other. The Hydraulic Fracturing segment intends to optimize hydrocarbon flow paths during the completion phase of horizontal shale wellbores. The Wireline segment includes wireline and ancillary services on new oil well completions in the Permian Basin. The Cementing segment provides isolation between fluid zones behind the casing to minimize potential damage to hydrocarbon bearing formations or the integrity of freshwater aquifers and provides structural integrity for the casing by securing it to the earth. The company was founded by Dale Redman and Jeffrey David Smith in 2005 and is headquartered in Midland, TX.

ProPetro Holding Corp

ProPetro ($PUMP) is trending amidst discussions around high trading volume and price fluctuations, with some traders eyeing it for potential shorting opportunities. The community is actively discussing the stock's potential for buybacks and its presence in the Solana ecosystem. Recent news includes insider trading activity and analyst ratings adjustments, influencing investor sentiment.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as investors debate its valuation amid a broader surge in quantum computing stocks; the community is split between those touting long-term potential and others pointing to financial losses and share dilution. Discussions also involve comparing RGTI's metrics and facilities to both established tech companies and other quantum computing firms. Some traders are closely watching for potential pullbacks or offering announcements.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending amid community excitement surrounding its timeless narrative and strong community, with many viewing it as a second chance to get into Bitcoin early. Discussions highlight the token's potential for significant growth and its unique position as the tokenization of Satoshi Nakamoto's legacy. The community is rallying around the idea that $SATOSHI represents the identity of the entire crypto industry.

TON (The Open Network) is a general-purpose blockchain that allows developers to build decentralized apps and tokens.

Toncoin

Toncoin is trending as community members discuss its potential integration with Telegram and recent listing on Robinhood, which some believe could significantly boost its visibility and adoption. There's also buzz around Verb Technology's substantial Toncoin holdings and strategic shift towards the TON ecosystem. Discussions include speculation on price movements and potential for future growth within the broader web3 landscape.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI is trending as the community rallies around it as the next big meme coin, drawing comparisons to earlier runs by $DOGE and $SHIB. Community members highlight the token's presence across multiple platforms and the potential for significant growth, with some suggesting a CoinMarketCap listing is on the horizon. The coin is associated with the $SOL ecosystem and a shared sense of optimism.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A White House official reportedly said on Friday that countries with existing trade agreements with the U.S. would be exempt from the recently announced pharmaceutical tariffs.&nbsp;According to a Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3U402V:0-latest-drug-tariffs-don-t-apply-to-nations-with-trade-deals-white-house-says/">cited</a> by TradingView, when asked whether pharmaceutical tariffs would apply to trading partners such as the European Union and Japan, which already have trade deals, the official stated that the Trump administration would honor the 15% cap as part of those pacts. Other nations with U.S. trade deals include Vietnam, the U.K., Indonesia, and the Philippines. Major partners like India, Canada, and Mexico have yet to finalize&nbsp;an agreement.The clarification comes after President Donald Trump on Thursday announced a 100% tariff on imported, branded, and patented pharmaceutical drugs starting October 1. In his Truth Social&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/115267512131958759">post</a> announcing the tariffs, Trump only highlighted that an exception would be made for any company that is “IS BUILDING their Pharmaceutical Manufacturing Plant in America.” He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction’.”In a note to investors on Friday morning, Jefferies analyst Akash Tewari described the new pharmaceutical tariffs as "a win for Pharma" and "a light at the end of the Trump tunnel," noting that several large-cap companies have already announced U.S. manufacturing projects. Tewari suggested the tariffs and the MFN pilot program may serve as a symbolic “on paper” win ahead of midterms, with limited material impact on pharmaceutical companies.The 100% tariff is higher than what Trump had indicated in August.&nbsp; He&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">stated</a> that tariffs would be increased over time, allowing companies sufficient time to build factories and relocate production. Trump had said he would start by charging a “small tariff” on pharmaceuticals and raise the rate over a year or more to 150% and even 250%.The&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF (IHE)</a> edged 1.3% higher in midday trade. On Stocktwits, retail sentiment around the ETF improved to ‘neutral’ from ‘bearish over the past day. Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rose 0.86% with retail sentiment trending in ‘bullish’ territory as chatter rose to ‘high’ from ‘normal’ levels.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pce-report-core-inflation-holds-steady-at-2-9-in-august/chDViYeR3eE">PCE Report: Core Inflation Holds Steady At 2.9% In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report

According to a Reuters report cited by TradingView, a White House official stated that the Trump administration will honor the 15% pharmaceutical tariff cap for trade partners such as the EU and Japan, as outlined in existing agreements.

Equity

Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

White House Press Secretary Karoline Leavitt said on Thursday that President Donald Trump is set to send out letters to 17 pharmaceutical company CEOs in the U.S., including Eli Lilly (LLY), giving them 60 days to address the global pricing disparity of drugs.“Other nations have been free-loading on U.S. innovation for far too long, and it is time they pay their fair share,” said Leavitt, reading out one of the letters, addressed to Eli Lilly CEO David A. Ricks.<a href="http://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dipped more than 1% in afternoon trade after the news broke. On Stocktwits, retail sentiment around the pharmaceutical giant remained in ‘bullish’ territory over the past day.Other pharma stocks also took a hit. Moderna (MRNA) extended its downtrend, dipping nearly 7%, AstraZeneca (AZN) slipped more than 3% and Pfizer (PFE) was down over 1%.&nbsp;The warning comes after Trump signed an executive order delivering ‘most favored nation’ prescription drug pricing for U.S. patients in May.The letter alleges that most of the proposals that the Trump administration has received to resolve the issue of drug pricing promised “more of the same, shifting blame, and requesting policy changes that would result in billions of dollars in handouts to the industry.”It outlines that drug makers have 60 days to achieve the following goals:- Extend the ‘most favored nation’ pricing to Medicaid- Guarantee ‘most favored nation’ pricing for newly launched drugs- Return increased revenues abroad to American patients and taxpayers- Provided for direct purchasing at ‘most favored nation’ pricing“But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” warned the letter, adding that the Trump administration, U.S. Health Secretary Robert Kennedy Jr. and Centers for Medicare and Medicaid Services (CMS) administrator Mehmet Oz stand ready to implement these terms.&nbsp;According to the letter, the companies have till September 29 to comply.&nbsp;The VanEck Pharmaceutical ETF (PPH) dropped more than 2%, while the iShares U.S. Pharmaceutics ETF (IHE) edged 0.8% lower.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-chair-unveils-project-crypto-to-back-trump-push-for-us-crypto-dominance/choLhyMRdG4">SEC Chair Unveils ‘Project Crypto’ To Back Trump’s Push For US Crypto Dominance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Donald Trump gestures during a meeting with British Prime Minister Keir Starmer (not pictured) on July 28, 2025 in Turnberry, Scotland. (Photo by Christopher Furlong/Getty Images)

Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing 

The U.S. President is expected to send out these letters through his social media platform, Truth Social.

AstraZeneca stock climbed nearly 3% in Tuesday’s early premarket session after the Cambridge, U.K.-based biopharma giant reported a beat for the second quarter of the fiscal year 2025 and reiterated its full-year outlook.The company reported second-quarter core earnings per share (EPS) of $1.58, a 27% increase year over year (YoY), and revenue of $14.46 billion, representing a 12% rise.&nbsp;The results exceeded the company's compiled consensus estimates of $2.16 billion and $14.46 billion, respectively, Reuters reported.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/AZN">AstraZeneca stock</a> stayed ‘bullish’ (57/100) early Tuesday, and the 24-hour message volume was also at ‘high levels.<figure class="image"><img style="aspect-ratio:618/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_29_at_5_24_42_AM_png_b578c580c0.webp" alt="Screenshot 2025-07-29 at 5.24.42 AM.png" width="618" height="58"><figcaption>AZN stock sentiment and message volume as of 5:20 a.m. ET, July 29 | source: Stocktwits</figcaption></figure>A bullish watcher lauded the company for an “excellent earnings report.”<stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/622814998</stembedurl>Product sales rose 11% to $13.80 billion, or 95.4% of the total revenue, thanks to double-digit growth in Oncology and biopharmaceutical sales.&nbsp;Its oncology franchise fetched revenue of $6.32 billion, accounting for 44% of the total revenue and witnessing 18% growth. Imfinzi and Tagrisso sales jumped 10% and 13%, respectively.Respiratory and Immunology Revenue climbed 13% to $2.15 billion, or 15% of the total.The company said all the major geographical regions saw YoY revenue growth. The U.S., which accounted for 43% of the company's total revenue, experienced 13% growth.&nbsp;AstraZeneca CEO Pascal Soriot said, “Our strong momentum in revenue growth continued through the first half of the year … with 12 positive key Phase III trial readouts including for baxdrostat, gefurulimab, and Tagrisso in just the past few weeks.”Looking ahead, AstraZeneca reiterated its revenue and core EPS growth guidance for the fiscal year 2025, expecting high-single-digit constant currency revenue growth and low double-digit core EPS growth.Soriot noted that the company has pledged $50 billion to expand in the U.S., its key market, amid President Donald Trump’s push to bring manufacturing back onshore. The company is making its biggest-ever investment in a manufacturing facility in Virginia.He reiterated the company’s long-term goal of hitting $80 billion in revenue by 2030.AstraZeneca’s U.S.-listed shares have gained about 4.6% this year, underperforming the broader market.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stellantis-stock-slides-premarket-as-auto-giant-reinstated-guidance-leaves-investors-unimpressed/cho9oJ1R5Ug">Stellantis Stock Slides Premarket As Auto Giant’s Reinstated Guidance Leaves Investors Unimpressed</a>

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers

Product sales rose 11% to $13.80 billion, or 95.4% of the total revenue, thanks to double-digit growth in Oncology and biopharmaceutical sales.

Merck (MRK) announced on Monday that the Canadian regulator, Health Canada, has granted approval for its cancer drug Keytruda in combination with chemoradiotherapy (CRT) for the treatment of advanced-stage cervical cancer.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRK">Merck</a> trended in the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:1366/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_21_at_11_37_27_AM_png_3a0152bdf1.webp" alt="MRK's Sentiment Meter and Message Volume as of 11:37 a.m. ET on July 21, 2025 | Source: Stocktwits" width="1366" height="128"><figcaption>MRK's Sentiment Meter and Message Volume as of 11:37 a.m. ET on July 21, 2025 | Source: Stocktwits</figcaption></figure>The approval is <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newswire.ca/news-releases/health-canada-approves-keytruda-r-for-the-treatment-of-adult-patients-with-figo-2014-stage-iii-iva-cervical-cancer-in-combination-with-chemoradiotherapy-crt-1-810218043.html">based</a> on data from the late-stage trial. The data demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in patients randomized to Keytruda in combination with CRT compared with patients randomized to placebo plus CRT. The trial enrolled 1,060 newly diagnosed patients.Cervical cancer forms in the cells lining the cervix, which is the lower part of the uterus. In 2024 alone, it was estimated that there were approximately 1,600 women diagnosed with cervical cancer and an estimated 400 deaths as a result of the disease, as per data from the Canadian Cancer Society.Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas.Meanwhile, Merck will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. Analysts on average expect the company to report earnings per share of $2.02, down from $2.28 per share in the corresponding quarter of 2024.Quarterly revenue is expected to be $15.86 billion, down from the $16.11 billion reported in the corresponding period of 2024.On Stocktwits, a user expressed optimism about the stock in light of the company’s restructuring plan, upcoming trial results, and solid financial position.<stembedurl>https://stocktwits.com/jjokerst/message/621710390</stembedurl>Another, however, sounded skeptical about the overall pharmaceutical and medical technology industry.<a href="https://stocktwits.com/YouOnlyLiveTwice/message/621754509">https://stocktwits.com/YouOnlyLiveTwice/message/621754509</a>Keytruda is Merck’s blockbuster cancer drug. In the three months through the end of March, Keytruda sales increased 4% to $7.2 billion, driven by a rise in global uptake in earlier-stage indications and continued strong demand worldwide.Through full year 2024, Keytruda total sales were $29.48 billion, accounting for about 46% of the company’s total sales.MRK stock is down 20% this year and approximately 37% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-sees-28-percent-slide-in-chatter-over-past-week/ch8kz4ZR5qy">Tesla Stock Sees 28% Slide In Retail Chatter Over Past Week Ahead Of Q2 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided

Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas. 

ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.


VanEck ETF Trust - VanEck Pharmaceutical ETF

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

PPH
VanEck Pharmaceutical ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PPH News

PPH VanEck Pharmaceutical ETF